Myovant Sciences filed a registration with the U.S. SEC for an IPO of its common stock. The proposed maximum offering price is $172.5 million.
Underwriters on the offering are Citigroup, Cowen and Company, Evercore ISI, and Barclays.
Myovant Sciences is a "clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for women’s health diseases and other endocrine-related disorders.
Underwriters on the offering are Citigroup, Cowen and Company, Evercore ISI, and Barclays.
Myovant Sciences is a "clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for women’s health diseases and other endocrine-related disorders.
